Vischer advised RLF in closing agreement with Sonnet BioTherapeutics
Relief Therapeutics Holding (RLF) announces the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, now a subsidiary of Sonnet BioTherapeutics Holdings (formerly known as Chanticleer Holdings) of Relief Therapeutics, a subsidiary of Relief Holding, signed August 12, 2019. As a consequence, Sonnet acquires all outstanding shares of Relief SA that becomes a wholly owned Geneva-based subsidiary of Sonnet. In counterpart, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock.
